A5056335083- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Inflammatory Biomarkers in Disease Prognosis
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Economic and Financial Impacts of Cancer
- PARP inhibition in cancer therapy
- Cancer therapeutics and mechanisms
- Lung Cancer Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Nutrition and Health in Aging
- Gastric Cancer Management and Outcomes
- Neuroendocrine Tumor Research Advances
- Cancer Cells and Metastasis
- BRCA gene mutations in cancer
- COVID-19 diagnosis using AI
- Genetic factors in colorectal cancer
- Ovarian cancer diagnosis and treatment
European Institute of Oncology
2022-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2024
Ripamonti
2023-2024
University of Milan
2024
University of Udine
2018-2023
Ospedale Santa Maria della Misericordia di Udine
2020-2022
Centro di Riferimento Oncologico
2018-2021
Platinum-based chemotherapy is the current standard treatment option in patients with
Endocrine therapy (ET) plus cyclin-dependent-kinases 4/6 inhibitors (CDK4/6i) represents the standard treatment for luminal-metastatic breast cancer (MBC). However, prospective head-to-head comparisons are still lacking 1st line (L) options, and it is crucial to define best strategy between 2nd L.
Abstract Background Monocyte-to-lymphocyte ratio (MLR) and lactate dehydrogenase (LDH) levels are circulating biomarkers that provide information about tumor-related inflammation immune suppression. This study aimed to evaluate the prognostic role of MLR LDH in metastatic colorectal cancer (mCRC). Material Methods multicentric analyzed a consecutive cohort 528 patients with mCRC treated 2009–2017. The whole population was randomly divided training validation cohort. first used identify...
Endocrine therapy (ET) is the mainstay of treatment for hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer; however, adaptive mechanisms emerge in about 25-30% cases through alterations estrogen ligand-binding domain, with a consequent ligand-independent activity. Epigenetic-mediated events are less known and potentially involved alternative resistance. The aim this study was to test feasibility 1 (ESR1) epigenetic characterization...
Actionable driver mutations account for 40-50% of NSCLC cases, and their identification clearly affects treatment choices outcomes. Conversely, non-actionable are genetic alterations that do not currently have established implications. Among co-occurring alterations, the concurrent actionable genomic is a rare event, potentially impacting prognosis
Journal of Cancer Metastasis and Treatment is an open access journal, focusing on basic clinical studies related to cancer cell, cell biology, oncology, radiation therapy radiology, obstetrics gynecology, pediatrics, surgery, hematology, neuro-oncology, etc.
Triple-negative breast cancer (TNBC) is a subtype characterized by poorer prognosis. Despite that TNBC can display immunogenic features, anti-PD(L)1 monotherapy strategies have resulted in disappointing results, underscoring the need to optimize their use TNBC. Among many, combining immunotherapy with other agents exploit synergistic effect of different drugs has been explored. Such combination approach led approval immune checkpoint inhibitors (ICIs) plus chemotherapy both metastatic and...
Background: Emerging data suggest that gender-related immune system composition affects both response and efficacy of immunotherapy in cancer patients (pts). This study aimed to investigate the sex-related prognostic role MLR metastatic colorectal (mCRC) pts. Methods: We analyzed a retrospective consecutive cohort 490 mCRC treated from 2009 2018 at Oncology Departments Aviano Pordenone (training set) Udine (validation set), Italy. The impact on overall survival (OS) was evaluated with uni-...
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma accounting for 15% of cancers with dismal survival outcomes. Minimal changes in therapy and prognosis have occurred SCLC the past four decades. Recent progress treatment extensive-stage disease (ES-SCLC) has been marked by incorporating immune checkpoint inhibitors (ICIs) into platinum-based chemotherapy, leading to modest improvements. Moreover, few second-line-and-beyond options are currently available. The main...
Different de-escalation strategies have been proposed to limit the risk of cumulative toxicity and guarantee quality life during treatment trajectory patients with metastatic colorectal cancer (mCRC). Programmed interruptions, defined as drug holidays (DHs), implemented in clinical practice. We evaluated association between DHs overall survival (OS). This was a retrospective study, conducted at University Hospital Udine IRCCS CRO Aviano. retrieved records 608 consecutive treated for mCRC...
circulating tumor DNA (ctDNA) is a source of genetic material for EGFR testing in NSCLC. Real-word data about liquid biopsy (LB) clinical practice are lacking. The aim the study was to describe LB detection North Eastern Italy.we conducted multi-regional survey on ctDNA practices lung cancer patients.Median time from blood collection plasma separation 50 min (20-120 min), median extraction analysis 24 h (30 min-5 days) and turnaround (6 h-5 days). Four hundred seventy five patients 654...